Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry
NEW YORK, Oct. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Automated And Rapid Microbiological Tests Industry
http://www.reportlinker.com/p092467/Global-Automated-And-Rapid-Microbiological-Tests-Industry.html
This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US$ Million by the following end-use segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 125 companies including many key and niche players such as Abbott Laboratories, Abbott Diagnostics, Alere Inc., Becton Dickinson and Company, bioMerieux SA, bioMerieux, Inc., Bio-Rad Laboratories, Inc., Cellabs Pty Ltd, Celsis International Plc., Coris BioConcept, F. Hoffmann-La Roche Ltd., Gen-Probe Inc., Genzyme Diagnostics, MedMira Inc., Meridian Biosciences, Inc., Orasure Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Siemens Healthcare Diagnostics, Inc., Thermo Fisher Scientific, Inc., Remel, Inc., and Oxoid Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
AUTOMATED AND RAPID MICROBIOLOGICAL TESTS MCP-1093
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
Clinical Applications 4
Automated Identification and Susceptibility Systems 4
Automated Blood Culture Systems 4
Automated Tuberculosis Systems 5
Streptococcal Infection Rapid Tests 5
GC/Chlamydia Rapid Tests 5
Other Automated & Rapid Microbiological Tests 5
Non-Clinical Applications 5
2. INDUSTRY OVERVIEW 6
Outlook 6
Evolutionary Battle Against Bugs Drives Market Future 6
Automated Microbiological Tests: A Pesky Gray Area in the
Clinical Diagnostics Market 6
Traditional Rapid Microbiological Tests Destined to Go Out
With the Old 7
A Current & Future Analysis 7
Segmental Perspective 8
Clinical Applications 8
Non-Clinical Applications 8
Macro: The Big Picture 8
Deciding the Market's Future 9
A Holistic Peek into a Few Noteworthy Trends 9
Biotechnology & Rapid Microbial Tests 10
Automated & Rapid Microbiological Tests: "Current Market Stance" 11
A Business Case for Automated & Rapid Microbiological Testing 11
Near Patient Testing: An Offshoot of Rapid Microbiological Tests 11
Pros & Cons of Near Patient Testing 12
Role of Near Patient Testing in Reducing Antibiotic
Resistance in Humans 12
The Pre/Post Microbial Rapid Testing Era: A Review 13
Market Structure 13
Competitive Setup of the Diverse Automated & Rapid
Microbiology Products Market 13
Competitive Landscape 14
Table 1: World Market for Microorganism Identification and
Resistance Tests by Leading Players (2008): Market Share
Breakdown of Value Share for BioMerieux; Becton, Dickinson
and Co; Siemens AG; and Others (includes corresponding
Graph/Chart) 14
Table 2: World In-Vitro Diagnostics (IVD) Market by Leading
Players (2008): Market Share Breakdown for Roche, Siemens,
Abbott Diagnostics, Becton Dickinson, Beckman Coulter, OCD
, BioMerieux, Sysmex, Others (includes corresponding
Graph/Chart) 15
Table 3: World Blood Screening Market by Leading Players
(2008): Market Share Breakdown for Gen-Probe/Novartis,
Roche, Homebrew, and Others (includes corresponding
Graph/Chart) 15
3. TRENDS & ISSUES 16
Advancements in Molecular Diagnostics - A Boon or a Threat 16
Leading Companies in Molecular Diagnostics Market 16
Antibiotic Resistant Bacteria Throws the Spotlight On
Microbial Testing 16
Instant Detection of Pathogens - A New Epoch in the Fight for
Survival 17
Lower Cost Rapid Tests Built on Multiple Sampling Modalities -
Gaining Momentum 17
"Time Constraints?" - Rapid Tests to the Rescue 17
Rapid HIV Tests: A New Age Diagnostic Weapon Against the
Killer Disease 18
Accuracy/Reliability of Home HIV Testing: A Bone of Contention 18
Development of Near Patient Test Kits: A Market Driven Phenomenon 19
Near Patient Test Kits: A Rumination of Possibilities 19
Automated Blood Culture Systems: A Winning Edge in the Fight
Against Bacteremia 20
Leading Food Processors Resort to Rapid Microbiological Testing 20
Impact of Food Scares on Rapid Microbiological Tests Market 21
Demand for Microbiological Tests & Level of QC in the Food
Industry 22
Rapid Tests Creating Brighter Avenues in Food Microbiology
Testing Market 23
Dire Need to Nip Operating Costs Throws the Spotlight on Rapid
Tests 23
Key Advantages/Benefits of Rapid Microbiological Tests on Food 24
Food Packages of the Future Ingrained with Microbial Alert
Systems 24
Technology Innovations in Rapid Food Microbial Testing: A
Historic Brief 24
Obtaining Regulatory Approval - A Major Non-Technical Hindrance 25
4. FACTORS INFLUENCING THE MARKET 26
Continuing Biological Warfare with Pathogens Sparks Market Growth 26
Innovative Products - A Key Growth Strategy 26
Other Market Drivers in a Capsule 26
Low Turnaround Times Skyrocket Demand 26
Greater Patient Awareness 27
Rising Incidence of STDs Kindles Universal Market Acceptance 27
Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-
Epidemic 27
Validation of Rapid Microbiological Tests: An Imperative
Prerequisite 27
Non-Conformance to Testing Requirements: A Weighty Concern 28
Influenza - Boosting Rapid Test Prospects 29
5. PRODUCT/TECHNOLOGY OVERVIEW 30
Automated & Rapid Microbiological Tests: A Definition 30
Benefits of Automated & Rapid Microbiological Tests 30
Classification of Rapid Microbiological Test Methods 31
How Does a Rapid Test Work? 31
Sample Preparation - A Key Procedure 32
Automated Identification and Susceptibility Systems 32
Automated Blood Culture Systems 32
Automated Tuberculosis Systems 33
Microminiaturization of Diagnostic Tests: How Is It Effected? 33
Advantages of Microminiaturisation: 34
Acid-Fast Microscopy - The Forerunner of Rapid Tests 34
Gram's Stain: A Time-Honored & Rapid Method to Detect
Pathogens in Blood 34
Enabling Technologies of Automated & Rapid Microbiological Tests 35
Growth-based Technologies 35
Viability-based Technologies 35
Cellular-Component or Artifact-based Technologies 36
Genomics/ Proteomics 36
Microarrays/Microfluidics 36
DNA Microchips/Probes 37
Polymerase Chain Reaction (PCR) 37
Immunoassay 37
Immunoassay Escalates into Diverse Fields of Diagnostic Testing 38
Nucleic Acid Testing (NAT) 38
Nucleic Acid Probes 39
Signal-Amplified Tests 39
Nucleic Acid Amplification Tests 39
Traditional Methods with Computer-Aided Imaging 40
Combination Methods 40
6. END-USE APPLICATION ANALYSIS 41
Applications in Clinical Investigations 41
STD Rapid Tests 41
GC/Chlamydia Rapid Tests 41
HIV Rapid Tests 42
HIV Facts & Figures 43
Table 4: Global Prevalence of HIV Infection by Region:
2007 & 2008 (includes corresponding Graph/Chart) 43
Table 5: Global HIV Related Deaths by Region: 2007 & 2008
(includes corresponding Graph/Chart) 44
Table 6: Global Distribution of HIV Prevalence, Incidence
and Mortality: 2008 (includes corresponding Graph/Chart) 44
Advantages of Rapid HIV Testing 45
Disadvantages of Rapid HIV Testing 45
Syphilis Rapid Tests 45
Respiratory Rapid Tests 45
RSV/ Influenza Rapid Tests 46
Tuberculosis Rapid Tests 46
Group A beta Hemolytic Streptococcus Rapid Tests 46
Mononucleosis Rapid Tests 47
Streptococcus Rapid Tests 47
Streptococcus A Rapid Tests 47
Streptococcus B Rapid Tests 48
Gastrointestinal Rapid Tests 48
Giardia Lamblia Rapid Tests 48
H. Pylori Rapid Tests 49
Cryptosporidium Rapid Tests 49
C. Difficile Rapid Tests 50
Applications in Non-Clinical Investigations 50
Food/Water Safety Tests 50
Food Safety Testing: A Lucrative Application Area 50
Rapid Microbiological Methods in Pharmaceutical Sector 51
Limitations of RMMs 52
Advantages of RMMs 52
Applications in Pharmaceutical Sector 52
Environmental Tests 53
Other Miscellaneous Applications 53
7. PRODUCT INNOVATIONS/INTRODUCTIONS 54
Alere Rolls Out three Cardiac Testing Solutions 54
Millipore Introduces New Milliflex Quantum Rapid
Microbiological Test Method 54
BD Diagnostics Adds Automated Microbiology Specimen Processor
to its Diagnostic Portfolio 54
Roche Introduces New Automatic Clinical Laboratory System,
Cobas®4800 55
Thermo Fisher Scientific Launches an Automated Photometric Method 55
Thermo Fisher Scientific Introduces Salmonella Rapid Culture
Method 56
BD Receives FDA Clearance for BD ProbeTec Amplified DNA Assays
on BD Viper System 56
Oxoid Introduces Xpect® Flu A&B 56
Oxoid Extends ProSpecT Range 56
Oxoid Launches ELISA Systems Test Kits Range 57
Oxoid Introduces Brilliance VRE Agar and Brilliance ESBL Agar 57
Oxoid Launches RapID Kits 58
Inverness Medical Innovations Introduces C. DIFF QUIK CHEK
COMPLETETM Rapid Test 58
Celsis International Launches Celsis ReACTTM 59
Roche Diagnostics Introduces LightCycler® Mycobacterium
Detection Kit 60
bioMerieux Introduces NucliSENS EasyQ® HIV-1 v2.0 60
Celsis International Unveils RapiScreenTM Beverage 61
Siemens Launches MicroScan Synergies plus® gram-positive ID/
MIC and MIC Combination Panels 61
Oxoid Introduces IDEIATM Norovirus 61
Oxoid Introduces Salmonella PrecisTM Process 62
Remel Offers FDA Approved RPMI 1640 Agar w/MOPS and 2% Glucose 62
Oxoid Launches Rapid MDG Broth 62
Lonza Introduces microCompass TYMC (Total Yeast and Mould
Count) Detection Kit 63
Inverness Medical Introduces Determine HIV-1/2 Ag/Ab Combo 63
Meridian Bioscience Rolls Out Two New Rapid Tests for
Detecting Epstein-Barr Virus 64
Oxoid Introduces Staph Plus System for Identifying
Staphylococcal Species 64
8. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST - A
PERSPECTIVE BUILDER 65
Siemens Healthcare Diagnostics Launches MicroScan® WalkAway®
plus Diagnostic Microbiology Systems 65
Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™
test, in US 65
bioMerieux Introduces VIDAS®, an automated Clostridium
difficile A & B Toxins Detection Test 65
Oxoid Launches Remel Wellcolex® Colour Tests for Testing
Shigella, E. coli O157 and Salmonella 66
Siemens Healthcare Diagnostics Obtains Health Canada Approval
for its VERSANT 440 Molecular System 66
Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test 66
Neogen Introduces Soleris System 66
ATCC Introduces Authenticult™ Quality Control Microbiological
Testing Tool 67
Bio-Rad Introduces New EBV Kits 67
Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test 67
Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test 67
FDA Clears Usage of TIGRIS® System for Testing WNV in Donated
Blood 68
FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli
Infection 68
bioMerieux Introduces TEMPO® Quality Indicator Testing System 68
Biotrace Introduces Tecra Unique Campylobacter Rapid Test 68
bioMerieux Introduces TEMPO® EB test for Enterobacteriaceae 69
Roche Unveils Elecsys TORCH Assays 69
Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan 69
bioMerieux Develops Advanced Colorimetry™ NH Card 69
Roche Introduces Rapid LightCycler SeptiFast Sepsis Test
across EU 69
Oxoid Launches New Rapid Test for Salmonella Detection in Food
Products 70
Oxoid Unveils New Contact Plate Design 70
FDA Approves Fluconazole Susceptibility Tests from BioMerieux 70
Polysciences Unveils New Microbiological & Bacterial Detection
Applications 70
Researchers Develop New Rapid MODS Test for TB Detection 71
Dade Behring Unveils Automated Quadriga BeFree System 71
FDA Approves Abbott PRISM® HBsAg Assay 71
Bayer's EHIV Test Receives FDA Clearance 72
Gen-Probe Obtains FDA Approval to Use Aptima Test on
Additional Specimens 72
Roche Diagnostics' cobas TaqScreen MPX Test Receives CE Mark
Approval 72
Cepheid Introduces Rapid Xpert® MRSA Test in Europe 72
Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella 73
Chemogen Develops New Tuberculosis Rapid Test 73
bioMerieux Rolls Out VIDAS® LDUO Test 73
Zonda Develops New Rapid Test for Chlamydia 73
MedMira Launches MiraCare Rapid HIV Test 73
STMicroelectronics and Mobidiag Unveil Lab-On-Chip 73
Vermicon Launches ScanVIT-Legionella Rapid Test Kit 74
New Line of Rapid Microbial Detection Systems from Centrus 74
OraSure Rolls Out OraQuick ADVANCE 74
Abbott Unveils Automated HCV Test 74
ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and
Respiratory Pathogens 74
Biophage Pharma Offers Service for Microbiological Testing 75
bioMerieux Releases New Rapid Test for Nosocomial Infections 75
bioMerieux Widens Product Portfolio with Addition of TEMPO®
System 75
9. RECENT INDUSTRY ACTIVITY 76
Inverness Medical Adopts New Corporate Identity 76
Thermo Fisher Acquires Ahura Scientific 76
Don Whitley Signs Distribution Agreement with Zisys 76
Charm Sciences Acquires MLX Microplate Luminometer Product
Line from Dynex Technologies 77
Alpha Analytical Acquires Boston Analytical Inc. 77
Roche Group Acquires Genentech 77
Roche Acquires Innovatis AG 78
3M Takes Over Biotrace International 78
Lab21 Buys Majority Stake in Biotec Laboratories 78
Vacci-Test Acquires Maxivet 79
bioMerieux Acquires PML Microbiologicals 79
3M Acquires Food Diagnostics AS 79
Becton, Dickinson and Company Receives License for its
GeneOhmTM from Health Canada 80
BD Diagnostics Receives CE Marking for BD GeneOhmTM VanR Test 80
bioMerieux Bags AOAC Research Institute's Performance- Tested
Methods SM Approval 80
MedMira Receives Sales Approval of Multiplo HBV/HIV/HCV Rapid
Tests Market 80
Schering-Plough Inks International Collaboration Agreement
with OraSure Technologies 81
Roche Selects Quidel's Influenza Test 81
Quidel Enters into Global Alliance with bioMerieux 82
Premier's QUEST Selects Remel SpectraTM MRSA 82
Thermo Fisher Scientific and MedAssets Supply Chain Systems
Enter into a Supply Agreement 82
Thermo Fisher Scientific Bags FDA Approval for SpectraTM MRSA 82
Advantest to Take Over Credence Systems 83
DSM Food Specialties to Acquire CMT Srl 83
Sysmex Signs Agreement with bioMerieux 83
Nanogen Enters into Definitive Agreement with Elitech Group 84
Silliker Acquires Majority Stake in EGI Laboratory 84
BD Establishes New Rapid Diagnostic Products Manufacturing
Facility in China 84
Quidel Corporation Obtains CLIA Waiver from US FDA for its
QuickVue(R) RSV Test 84
Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular
System 85
bioMerieux to Market Wescor's Customized Slide Stainer
Instruments under bioMerieux Brand 85
Schering-Plough and OraSure Ink Collaboration Agreement for
Developing Rapid Oral HCV Test 85
Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-
II Blood Screening Test 86
Quidel and bioMerieux Form a Long-term Alliance in Rapid
Diagnostic Tests 86
BD Diagnostics Obtains US FDA Approval for BD GeneOhm™ StaphSR
Assay 86
10. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 87
Siemens Acquires Dade Behring 87
Concateno Acquires Euromed 87
Meridian Bioscience Obtains US FDA Approval for Two New Rapid
Tests 87
Thermo Fisher Scientific Teams Up with KBA for Expanding its
Microbiology Business Division in Lenexa 87
OraSure and SCMS Enter into an Agreement for Supplying
OraQuick(R) HIV Test to PEPFAR Countries 88
Abbott Obtains US FDA Approval for its Fully Automated PRISM®
HCV Test 88
Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS®
System for Testing Donated Blood 88
AdvanDx Ropes In bioMerieux for Distributing its Rapid
Diagnostic Tests in US 88
3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests
For Detecting HAIs 89
Gen-Probe's PROCLEIX® TIGRIS® System Obtains US FDA Approval
for Screening Donated Blood for West Nile Virus 89
3M Acquires Acolyte Biomedica 89
Formation of Siemens Medical Solutions Diagnostics 90
bioMerieux Bags Contract to Provide VITEK® 2 System for
Scottish NHS Labs 90
bioMerieux Licenses NorChip's HPV Test Technology for Cervical
Cancer 91
bioMerieux in Strategic Agreement with Cepheid for Sepsis Assays 91
3M Health Care Creates New Medical Diagnostics Unit 91
Schering-Plough & OraSure to Develop Rapid Oral HCV Test 92
3M Acquires Biotrace International 92
Siemens Acquires DPC 92
Oxoid Acquires Microbiology Business Activities of Dako 93
Inverness Acquires IDT and Thermo BioStar 93
BMD in Agreement with MND for Research on Diagnostic Tests 93
Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus
Detection Test 93
Dutch Government Grants €7.9 Million to FIND 94
FIND and Hain to Develop Rapid Test for MDR and XDR TB 94
3M & Gen-Probe Ally for Developing Rapid Molecular Tests for
Food Safety 94
Bio View Inks Three-Year Distribution Agreement with Abbott
Molecular 95
Bodycote Acquires Foodscan Laboratories 95
Cepheid Bags STTR Funding for Development of Rapid TB Test 95
Abbott and Verax in Distribution Agreement for Verax Platelet
PGD® Test 96
BSL Supplies ABBOTT PRISM® System to Blood Donor Testing Centers 96
Abbott & ARC in Agreement for Automated Blood Screening Tests 96
BD to Set Up Production Facility for Rapid Diagnostic Products
in China 97
BD Diagnostics Delivers STI Testing Products to BioReference 97
Meridian Licenses LAMP Diagnostic Test Technology from Eiken 97
OraSure Inks Multi-Year Purchase Contract with New York City 97
Abbott Inks Single-Source Agreement with Novation for HIV Test 98
Neogen Takes Over Centrus International 98
Becton, Dickinson and Company Acquires GeneOhm Sciences 98
Inverness Medical Innovations Makes a Synergetic Purchase of
ACON Laboratories 98
Quest Diagnostics Strikes Deal with BD Diagnostics 99
Novation Inks Pact with Abbott for Rapid HIV-1/2 Antibody Test 99
TREK Diagnostic and Novation Inks Agreement 99
Clinton Foundation Inks Agreement with Four Companies to Cut
Prices 99
Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure
Check HIV 1/2 Rapid Test PMAs 99
Roche's LightCycler SeptiFast Test Attains CE Mark 100
Zonda Expands Distribution of Products in Europe 100
OraSure Wins Rapid HIV Tests Order 100
MedMira Secures Orders for Rapid HIV Tests 100
Cepheid Collaborates with Foundation for Innovative Diagnostics 100
Chembio Obtains Clearance for Rapid HIV Tests in Kenya 101
Genesis Bioventures Bags US Patent for Rapid Prion- Detection
Assay 101
MedMira Obtains CE Mark for MiraCare 101
Setema to Distribute Chembio's Rapid HIV Tests in Ethiopia 101
Clinton Foundation HIV/AIDS Initiative Selects Chembio to
Provide Rapid HIV Tests 101
Quidel Acquires immunochemical Fecal Occult Blood Test 101
Xact Aid Snaps Up STD Alert 102
Grant Life Sciences Acquires Rapid Tests from AccuDx 102
Millipore Ties Up with Gen-Probe 102
Foundation for Innovative New Diagnostics forms Collaboration
with Eiken Chemical 102
WayPoint and Global Rapid Diagnostic Leader Enter into an
Agreement 102
Akers Biosciences Enters into a Distribution Agreement with
Alco Industries 103
Celsis and BioVentures Enter into Licensing Agreement 103
Thermo Electron Inks Pact with Genomic Profiling Systems 103
Abbott and OraSure Enters into Agreement for OraQuick ADVANCE
Rapid HIV-1/2 Test 103
bioMerieux Signs Agreement with Novel Diagnostics 103
Dade Behring Bags FDA Approval for Antimicrobial
Susceptibility Test Panels 103
OraSure Bags HCV Patent License from Chiron and Ortho-
Clinical Diagnostics 104
BD Diagnostics Receives FDA Approval for BD Directigen™ EZ Flu
A+B Test 104
BD Diagnostics Bags FDA Clearance for BBL™ CHROMagar™ MRSA
Product 104
MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou
Province, China 104
Gen-Probe Obtains FDA Clearance for PROCLEIX® West Nile Virus
Assay 104
Medical Services International Secures Clearance for Rapid
Test Kits 104
Medical Services International Receives Exclusive Marketing
Rights for TB Test Kit 105
Adaltis Receives Orders for HIV Rapid Tests from China 105
MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test 105
Genomic Profiling Systems Obtains NIAID Funds to Develop
Testing Platform 105
Gen-Probe Obtains US Patent for Automated Process for Nucleic
Acid Testing 105
Bio-Rad Receives Approval for HIV-1/HIV-2 Rapid Test 105
11. FOCUS ON SELECT GLOBAL PLAYERS 106
Abbott Laboratories (USA) 106
Abbott Diagnostics (USA) 106
Alere Inc. (US) 106
Becton Dickinson and Company (USA) 107
bioMerieux SA (France) 107
bioMerieux, Inc. (USA) 108
Bio-Rad Laboratories, Inc (USA) 108
Cellabs Pty Ltd (Australia) 108
Celsis International Plc (UK) 109
Coris BioConcept (Belgium) 109
F. Hoffmann-La Roche Ltd. (Switzerland) 109
Gen-Probe Inc. (USA) 110
Genzyme Diagnostics (USA) 110
MedMira, Inc. (Canada) 111
Meridian Biosciences, Inc. (USA) 111
Orasure Technologies, Inc. (USA) 111
Orion Diagnostica Oy (Finland) 112
Quidel Corp. (USA) 112
Siemens Healthcare Diagnostics, Inc. (USA) 113
Thermo Fisher Scientific, Inc. (USA) 113
Remel, Inc. (USA) 113
Oxoid Limited (UK) 114
12. GLOBAL MARKET PERSPECTIVE 115
Table 7: World Recent Past, Current & Future Analysis for
Automated and Rapid Microbiological Tests by Geographic Region-
US, Europe, and Rest of World Independently Analyzed with
Annual Revenues in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 115
Table 8: World Historic Review for Automated and Rapid
Microbiological Tests by Geographic Region - US, Europe, and
Rest of World Independently Analyzed with Annual Revenues in
US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 116
Table 9: World 10-Year Perspective for Automated and Rapid
Microbiological Tests by Geographic Region - Percentage
Breakdown of Revenues for US, Europe, and Rest of World for
Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 117
Table 10: World Recent Past, Current & Future Analysis for
Automated and Rapid Microbiological Tests in Clinical
Applications by Geographic Region - US, Europe, and Rest of
World Independently Analyzed with Annual Revenues in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 118
Table 11:World Historic Review for Automated and Rapid
Microbiological Tests in Clinical Applications by Geographic
Region - US, Europe, and Rest of World Independently Analyzed
with Annual Revenues in US$ Million for Years 2000 through
2006 (includes corresponding Graph/Chart) 119
Table 12: World 10-Year Perspective for Automated and Rapid
Microbiological Tests in Clinical Applications by Geographic
Region - Percentage Breakdown of Revenues for US, Europe, and
Rest of World for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 120
Table 13: World Recent Past, Current & Future Analysis for
Automated and Rapid Microbiological Tests in Clinical
Applications by Equipment Used - Automated Identification &
Susceptibility Systems, Automated Blood Culture Systems,
Automated Tuberculosis Systems, Streptococcal Infection Rapid
Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid
Microbiological Tests Independently Analyzed with Annual
Revenues in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 121
Table 14: World Historic Review for Automated and Rapid
Microbiological Tests in Clinical Applications by Equipment
Used - Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis
Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia
Rapid Tests and Other Automated & Rapid Microbiological Tests
Independently Analyzed with Annual Revenues in US$ Million for
Years 2000 through 2006 (includes corresponding Graph/Chart) 122
Table 15: World 10-Year Perspective for Automated and Rapid
Microbiological Tests in Clinical Applications by Equipment
Used - Percentage Breakdown of Revenues for Automated
Identification & Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems, Streptococcal
Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other
Automated & Rapid Microbiological Tests for Years 2005,2010 &
2015 (includes corresponding Graph/Chart) 123
Table 16: World Recent Past, Current & Future Analysis for
Automated Identification & Susceptibility Systems in Clinical
Applications by Geographic Region - US, Europe, and Rest of
World Independently Analyzed with Annual Revenues in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 124
Table 17: World Historic Review for Automated Identification &
Susceptibility Systems in Clinical Applications by Geographic
Region - US, Europe, and Rest of World Independently Analyzed
with Annual Revenues in US$ Million for Years 2000 through
2006 (includes corresponding Graph/Chart) 125
Table 18: World 10-Year Perspective for Automated
Identification & Susceptibility Systems in Clinical
Applications by Geographic Region - Percentage Breakdown of
Revenues for US, Europe, and Rest of World for Years 2005,
2010 & 2015 (includes corresponding Graph/Chart) 126
Table 19: World Recent Past, Current & Future Analysis for
Automated Blood Culture Systems in Clinical Applications by
Geographic Region - US, Europe, and Rest of World
Independently Analyzed with Annual Revenues in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 127
Table 20: World Historic Review for Automated Blood Culture
Systems in Clinical Applications by Geographic Region - US,
Europe, and Rest of World Independently Analyzed with Annual
Revenues in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 128
Table 21: World 10-Year Perspective for Automated Blood
Culture Systems in Clinical Applications by Geographic Region
- Percentage Breakdown of Revenues for US, Europe, and Rest of
World for Years 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 129
Table 22: World Recent Past, Current & Future Analysis for
Automated Tuberculosis Systems in Clinical Applications by
Geographic Region - US, Europe, and Rest of World
Independently Analyzed with Annual Revenues in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 130
Table 23: World Historic Review for Automated Tuberculosis
Systems in Clinical Applications by Geographic Region - US,
Europe, and Rest of World Independently Analyzed with Annual
Revenues in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 131
Table 24: World 10-Year Perspective for Automated Tuberculosis
Systems in Clinical Applications by Geographic Region -
Percentage Breakdown of Revenues for US, Europe, and Rest of
World for Years 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 132
Table 25: World Recent Past, Current & Future Analysis for
Streptococcal Infection Rapid Tests in Clinical Applications
by Geographic Region - US, Europe, and Rest of World
Independently Analyzed with Annual Revenues in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 133
Table 26: World Historic Review for Streptococcal Infection
Rapid Tests in Clinical Applications by Geographic Region -
US, Europe, and Rest of World Independently Analyzed with
Annual Revenues in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 134
Table 27: World 10-Year Perspective for Streptococcal
Infection Rapid Tests in Clinical Applications by Geographic
Region - Percentage Breakdown of Revenues for US, Europe, and
Rest of World for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 135
Table 28: World Recent Past, Current & Future Analysis for
GC/Chlamydia Rapid Tests in Clinical Applications by
Geographic Region - US, Europe, and Rest of World
Independently Analyzed with Annual Revenues in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 136
Table 29: World Historic Review for GC/Chlamydia Rapid Tests
(*) in Clinical Applications by Geographic Region - US,
Europe, and Rest of World Independently Analyzed with Annual
Revenues in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 137
Table 30: World 10-Year Perspective for GC/Chlamydia Rapid
Tests in Clinical Applications by Geographic Region -
Percentage Breakdown of Revenues for US, Europe, and Rest of
World for Years 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 138
Table 31: World Recent Past, Current & Future Analysis for
Other Automated & Rapid Microbiological Tests in Clinical
Applications by Geographic Region - US, Europe, and Rest of
World Independently Analyzed with Annual Revenues in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 139
Table 32: World Historic Review for Other Automated & Rapid
Microbiological Tests in Clinical Applications by Geographic
Region - US, Europe, and Rest of World Independently Analyzed
with Annual Revenues in US$ Million for Years 2000 through
2006 (includes corresponding Graph/Chart) 140
Table 33: World 10-Year Perspective for Other Automated &
Rapid Microbiological Tests in Clinical Applications by
Geographic Region - Percentage Breakdown of Revenues for US,
Europe, and Rest of World for Years 2005, 2010 & 2015
(includes corresponding Graph/Chart) 141
Table 34: World Recent Past, Current & Future Analysis for
Automated and Rapid Microbiological Tests in Non-Clinical
Applications by Geographic Region - US, Europe, and Rest of
World Independently Analyzed with Annual Revenues in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 142
Table 35: World Historic Review for Automated and Rapid
Microbiological Tests in Non-Clinical Applications by
Geographic Region - US, Europe, and Rest of World
Independently Analyzed with Annual Revenues in US$ Million for
Years 2000 through 2006 (includes corresponding Graph/Chart) 143
Table 36: World 10-Year Perspective for Automated and Rapid
Microbiological Tests in Non-Clinical Applications by
Geographic Region - Percentage Breakdown of Revenues for US,
Europe, and Rest of World for Years 2005, 2010 & 2015
(includes corresponding Graph/Chart) 144
13. THE UNITED STATES 145
A.Market Analysis 145
A Current & Future Analysis 145
Rapid Microbiology Tests - A Competitive Profile 145
Consolidation in the Automated and Rapid Microbiological
Tests Market 145
Bioterrorism Tests - Gaining Prominence 146
Tracking Trends Across Product Segments 146
STD Rapid Tests 146
Market Share Trends of Leading Players in the Recent Past 146
Table 37: Leading Players in the US Market for
GC/Chlamydia Rapid Tests (2004 & 2005) - Percentage
Breakdown of Value Sales by Company for Gen-Probe, Abbott,
Becton Dickinson and Roche (includes corresponding
Graph/Chart) 147
Table 38: Leading Players in the US Market for Chlamydia
Rapid Tests (2004 & 2005) - Percentage Breakdown of Value
Sales by Company for Thermo Electron, Wampole / Inverness
Medical Innovations, and Quidel (includes corresponding
Graph/Chart) 147
Table 39: Leading Players in the US Market for Syphilis
Rapid Tests (2004 & 2005) - Percentage Breakdown of Value
Sales by Company for Becton Dickinson, Wampole/Inverness
Medical Innovations, and Others (includes corresponding
Graph/Chart) 148
Leading Players in HIV Rapid Testing Market 148
Gastrointestinal Rapid Tests 148
Market Share Data of Leading Players in the Recent Past 149
Table 40: Leading Players in the US Market for C.
Difficile Rapid Tests (2004 & 2005) -Percentage Breakdown
of Value Sales by Company for Wampole/Inverness Medical
Innovations, Meridian Biosciences, BioSite, Becton
Dickinson, Thermo Electron, and Others (includes
corresponding Graph/Chart) 149
Table 41: Leading Players in the US Market for
Cryptosporidium Rapid Tests (2004 & 2005) - Percentage
Breakdown of Value Sales by Company for Remel, Meridian
Biosciences, and Becton Dickinson (includes
correspondingGraph/Chart) 149
Table 42: Leading Players in the US Market for Rotavirus
Rapid Tests (2004 & 2005) - Percentage Breakdown of Value
Sales by Company for Meridian Biosciences,
FisherScientific, and Others (includes corresponding
Graph/Chart) 150
Table 43: Leading Players in the US Market for Giardia
Rapid Tests (2004 & 2005) - Percentage Breakdown of Value
Sales by Company for Remel, Meridian Biosciences, and
Becton Dickinson (includes corresponding Graph/Chart) 150
Respiratory Rapid Tests 150
Competition 151
Market Share Data of Leading Players in the Recent Past 151
Table 44: Leading Players in the US Market for Influenza
Rapid Tests (2004 & 2005) - Percentage Breakdown of
Value Sales by Company for Quidel, Becton Dickinson,
Thermo Electron, Binax and Others (includes
corresponding Graph/Chart) 151
Table 45: Leading Players in the US Market for RSV Rapid
Tests (2004 & 2005) - Percentage Breakdown of Value
Sales by Company for Becton Dickinson, Binax,Thermo
Electron and Others (includes corresponding Graph/Chart) 152
Table 46: Leading Players in the US Market for
Tuberculosis Rapid Tests (2004 & 2005) - Percentage
Breakdown of Value Sales by Company for Gen-Probe, and
Becton Dickinson 152
Table 47: Leading Players in the US Market for M.
Pneumoniae Rapid Tests (2004 & 2005) - Percentage
Breakdown of Value Sales by Company for Meridian
Biosciences, and Remel, Inc. 152
Table 48: Leading Players in the US Market for
Mononucleosis Rapid Tests (2004 & 2005) - Percentage
Breakdown of Value Sales by Company for Wampole, Remel,
Quidel, Thermo Electronand Others (includes
corresponding Graph/Chart) 153
Streptococcus Infection Rapid Tests 153
Market Share Data of Leading Players in the Recent Past 154
Table 49: Leading Players in the US Market for
Streptococcus A Rapid Tests (2004 & 2005) -Percentage
Breakdown of Value Sales by Company for Quidel, Thermo
Electron, Becton Dickinson, Genzyme and Others (includes
corresponding Graph/Chart) 154
A Peek into the Testing Practices of the US Food Industry 154
B.Market Analytics 155
Table 50: US Recent Past, Current & Future Analysis for
Automated & Rapid Microbiological Tests by End-Use Segment -
Clinical Applications (Automated Identification &
Susceptibility Systems, Automated Blood Culture Systems,
Automated Tuberculosis Systems, Streptococcal Infection
Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &
Rapid Microbiological Tests) and Non- Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million
for Years 2007 through 2015 (includes corresponding
Graph/Chart) 155
Table 51: US Historic Review for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification& Susceptibility
Systems, Automated Blood Culture Systems, Automated
Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million
for Years 2000 through 2006 (includes corresponding
Graph/Chart) 156
Table 52: US 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage
Breakdown of Revenues for Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid
Tests, and Other Automated & Rapid Microbiological Tests)
and Non-Clinical Applications for 2005, 2010 & 2015
(includes corresponding Graph/Chart) 157
Table 53: US Recent Past, Current & Future Analysis for
Rapid Microbiological Tests by End-Use Segment - Clinical
Applications (Streptococcus Infection Rapid Tests
{Streptococcus A, and Streptococcus B}, STD Rapid Tests
{GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests
{RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae,
Legionella, and Influenza} and Gastrointestinal Rapid Tests
{Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H.
Pylori}) and Non-Clinical Applications Independently
Analyzed with Annual Revenues in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) 158
Table 54: US Historic Review for Rapid Microbiological Tests
by End-Use Segment - Clinical Applications (Streptococcus
Infection Rapid Tests {Streptococcus A, and Streptococcus
B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis},
Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis,
Mycoplasma Pneumoniae, Legionella, and Influenza} and
Gastrointestinal Rapid Tests {Cryptosporidium, Giardia,
Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical
Applications Independently Analyzed with Annual Revenues in
US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 159
Table 55: US 10-Year Perspective for Rapid Microbiological
Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Streptococcus Infection Rapid
Tests {Streptococcus A, and Streptococcus B}, STD Rapid
Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid
Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma
Pneumoniae, Legionella, and Influenza} and Gastrointestinal
Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C.
Difficile, and H. Pylori}) and Non-Clinical Applications for
2005, 2010 & 2015 (includes corresponding Graph/Chart) 160
14. EUROPE 161
A.Market Analysis 161
A Current & Future Analysis 161
European Market Primer 161
What Drives the Requirement Patterns of End-Users? 161
Trends & Issues 162
Proliferation of Automated, and Rapid Tests in Europe 162
European Automated Market 163
Probe Tests: "A Crack in the Future of Rapid Tests" 163
Trends Across Product Segments 163
GC/Chlamydia Rapid Tests 163
Streptococcal Infection (Strep A) Rapid Tests 163
Automated Tuberculosis Systems Market 164
Market Share Data of Leading Players - A Historic Perspective 164
Table 56: Leading Players in European Market for Automated
& Rapid Microbiological Tests (2000) - Percentage Breakdown
of Value Sales by Company for bioMerieux, Becton Dickinson,
Organon Teknika, Merlin, Abbott, Dade, Unipath, and Others
(includes corresponding Graph/Chart) 164
Table 57: Leading Players in European Market for Chlamydia
Rapid Tests (2000) - Percentage Breakdown of Value Sales by
Company for Abbott, Oxoid, Unipath, Quidel, and Others
(includes corresponding Graph/Chart) 164
Table 58: Leading Players in European Market for
Streptococcal Infection (Strep A) Rapid Tests (2000) -
Percentage Breakdown of Value Sales by Company for Abbott,
Unipath, Quidel, Orion Diagnostics, Oxoid, and Becton
Dickinson (includes corresponding Graph/Chart) 165
B.Market Analytics 165
Table 59: European Recent Past, Current & Future Analysis
for Automated & Rapid Microbiological Tests by Geographic
Region - France, Germany, The United Kingdom, Italy, Spain,
Russia, & Rest of Europe Independently Analyzed with Annual
Revenues in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 165
Table 60: European Historic Review for Automated & Rapid
Microbiological Tests by Geographic Region - France,
Germany, The United Kingdom, Italy, Spain, Russia, & Rest of
Europe Independently Analyzed with Annual Revenues in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 166
Table 61: European 10-Year Perspective for Automated & Rapid
Microbiological Tests by Geographic Region - Percentage
Breakdown of Revenues for France, Germany, The United
Kingdom, Italy, Spain, Russia, & Rest of Europe for Years
2005, 2010 & 2015 (includes corresponding Graph/Chart) 167
Table 62: European Recent Past, Current & Future Analysis
for Automated & Rapid Microbiological Tests by End-Use
Segment - Clinical Applications (Automated Identification &
Susceptibility Systems, Automated Blood Culture Systems,
Automated Tuberculosis Systems, Streptococcal Infection
Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &
Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million
for Years 2007 through 2015 (includes corresponding
Graph/Chart) 168
Table 63: European Historic Review for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated
Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million
for Years 2000 through 2006 (includes corresponding
Graph/Chart) 169
Table 64: European 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage
Breakdown of Revenues for Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid
Tests, and Other Automated & Rapid Microbiological Tests)
and Non-Clinical Applications for 2005, 2010 & 2015
(includes corresponding Graph/Chart) 170
14a. FRANCE 171
A.Market Analysis 171
A Current & Future Analysis 171
bioMerieux: A Key Player 171
Market Share Data of Leading Players - A Historic Perspective 172
Table 65: Leading Players in French Market for Automated &
Rapid Microbiological Tests (2000) - Percentage Breakdown
of Value Sales by Company for bioMerieux, Becton
Dickinson, Merlin, Organon Teknika, Dade, Pasteur Sanofi
Diagnostic, Oxoid and Abbott (includes corresponding
Graph/Chart) 172
To order this report:
Diagnostics Industry: Global Automated And Rapid Microbiological Tests Industry
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT: |
|
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article